e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lack of penetration of amikacin into saliva of tuberculosis patients
Simone H.J. van den Elsen, Onno W. Akkerman, Justine R. Huisman, Daan J. Touw, Tjip S. van der Werf, Mathieu S. Bolhuis, Jan-Willem C. Alffenaar
Source:
Eur Respir J, 51 (1) 1702024; 10.1183/13993003.02024-2017
Journal Issue:
January
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Simone H.J. van den Elsen, Onno W. Akkerman, Justine R. Huisman, Daan J. Touw, Tjip S. van der Werf, Mathieu S. Bolhuis, Jan-Willem C. Alffenaar. Lack of penetration of amikacin into saliva of tuberculosis patients. Eur Respir J, 51 (1) 1702024; 10.1183/13993003.02024-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis
Source: Eur Respir J 2016; 47: 1229-1234
Year: 2016
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients
Source: Eur Respir J 2013; 42: 1614-1621
Year: 2013
Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016
Year: 2017
Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis
Source: Eur Respir J, 51 (2) 1702166; 10.1183/13993003.02166-2017
Year: 2018
Reduced moxifloxacin exposure in patients with tuberculosis and diabetes
Source: Eur Respir J, 54 (3) 1900373; 10.1183/13993003.00373-2019
Year: 2019
Amoxicillin concentrations in sputum in relation to betalactamase activity in COPD patients
Source: Annual Congress 2011 - Role of infection in exacerbations of COPD
Year: 2011
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
In vitro
activity of moxifloxacin and linezolid against mycobacteria
Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis
Year: 2008
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China
Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020
Year: 2021
Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection in which Streptococcus pyogenes was isolated in sputum culture
Source: Eur Respir J 2004; 24: Suppl. 48, 414s
Year: 2004
Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance
Source: Eur Respir J, 50 (1) 1700598; 10.1183/13993003.00598-2017
Year: 2017
Detection of isoniazid or rifampin resistant
Mycobacterium tuberculosis
in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay
Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Year: 2005
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience
Source: Eur Respir J 2011; 38: 888-894
Year: 2011
Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients
Source: Eur Respir J, 53 (4) 1802107; 10.1183/13993003.02107-2018
Year: 2019
The role of moxifloxacin in tuberculosis therapy
Source: Eur Respir Rev 2015; 25: 19-28
Year: 2016
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 42: 504-512
Year: 2013
In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis
Source: Eur Respir J 2014; 44: 808-811
Year: 2014
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept